Unknown

Dataset Information

0

Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS.

ABSTRACT: The casein kinase 1A1 gene (CSNK1A1) is a putative tumor suppressor gene located in the common deleted region for del(5q) myelodysplastic syndrome (MDS). We generated a murine model with conditional inactivation of Csnk1a1 and found that Csnk1a1 haploinsufficiency induces hematopoietic stem cell expansion and a competitive repopulation advantage, whereas homozygous deletion induces hematopoietic stem cell failure. Based on this finding, we found that heterozygous inactivation of Csnk1a1 sensitizes cells to a CSNK1 inhibitor relative to cells with two intact alleles. In addition, we identified recurrent somatic mutations in CSNK1A1 on the nondeleted allele of patients with del(5q) MDS. These studies demonstrate that CSNK1A1 plays a central role in the biology of del(5q) MDS and is a promising therapeutic target.

SUBMITTER: Schneider RK 

PROVIDER: S-EPMC4199102 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

The casein kinase 1A1 gene (CSNK1A1) is a putative tumor suppressor gene located in the common deleted region for del(5q) myelodysplastic syndrome (MDS). We generated a murine model with conditional inactivation of Csnk1a1 and found that Csnk1a1 haploinsufficiency induces hematopoietic stem cell expansion and a competitive repopulation advantage, whereas homozygous deletion induces hematopoietic stem cell failure. Based on this finding, we found that heterozygous inactivation of Csnk1a1 sensitiz  ...[more]

Similar Datasets

Proteomics Lenalidomide induces ubiquitination and degradation of casein kinase 1A1 in del(5q) MDS
2015-01-26 | MSV000079014 | MassIVE
Unknown Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)-Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q).
| S-EPMC9208896 | biostudies-literature
Unknown TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients.
| S-EPMC3791697 | biostudies-literature
Unknown Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS.
| S-EPMC4853910 | biostudies-literature
Unknown Age-related inflammatory bone marrow microenvironment induces ineffective erythropoiesis mimicking del(5q) MDS.
| S-EPMC5886057 | biostudies-literature
Unknown MMP9 inhibition increases erythropoiesis in RPS14-deficient del(5q) MDS models through suppression of TGF-? pathways.
| S-EPMC6759738 | biostudies-literature
Unknown Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) MDS.
| S-EPMC4118486 | biostudies-literature
Transcriptomics Epistasis between TIFAB and miR-146a, neighboring genes in del(5q) MDS
2016-09-29 | GSE87453 | GEO
Unknown Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor-TRAF6 signaling.
| S-EPMC4612089 | biostudies-literature
Unknown Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS.
| S-EPMC4017258 | biostudies-literature